Aims: A series of 1,4-dihydropyridine based compounds bearing benzylpyridinium moiety have been
designed and evaluated for in vitro anticancer activity against glioblastoma U87MG, lung cancer A549 and
colorectal adenocarcinoma Caco-2 cell lines using the MTT assay.
Method: Among these compounds, 7b, 7d, 7e, and 7f exhibited potent anticancer activity against the cell lines
tested. The cytotoxicity of the synthesized derivatives was compared to standard drugs (carboplatin, gemcitabine, and
Result: Thus, synthesized 1,4-dihydropyridines can be considered as the encouraging molecules for further drug
development as anticancer agents.